Reduced Dose of Salvage-line @entity8486 Monotherapy for Metastatic XXXX in Japan.

@entity1 @entity137 @entity66 @entity8486 @entity409 @entity448 @entity492 @entity14 @entity493
BACKGROUND: Salvage-line @entity8486 monotherapy exhibited a marked survival benefit for metastatic @entity14 (mCRC). However, the @entity137 of this regimen has resulted in the clinical use of a reduced dose of @entity8486 . @entity1 AND METHODS: Thirty-two Japanese mCRC @entity1 (median age=61 years) who had been treated with @entity8486 were retrospectively examined. RESULTS: Best objective response rate was 0% and @entity66 ( @entity66 ) was 31%. Median progression-free survival was 81 days and median overall survival was 233 days. Adverse events of any grade were observed in all @entity1 : 17 (53%) @entity1 suffered grade 3 or 4 adverse events including fatigue (13%), @entity448 (13%), hand-foot skin reaction (22%) and elevations of @entity493 aminotransferase/ @entity492 aminotransferase (19%/16%). One @entity1 with grade 5 @entity409 was identified (3%). Twenty-nine (91%) @entity1 required treatment dose reduction or a delay in treatment. The relative dose intensity was 59%. @entity8486 treatments were terminated because of disease progression (59%) or adverse events (34%). CONCLUSION: Despite a decrease in the intensity of @entity8486 treatment, because of severe adverse events, a fairly favorable efficacy was achieved in Japanese @entity1 .
